title: Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective.
abstract: OBJECTIVE
  To assess the potential effects of primary prevention with anticoagulants or aspirin in atrial fibrillation on Swedish population.
  
  
  METHODS
  Analysis of cost effectiveness based on the following assumptions: about 83,000 people have atrial fibrillation in Sweden, of whom 22,000 would be potential candidates for treatment with anticoagulants and 55,000 for aspirin treatment; the annual 5% stroke rate is reduced by 64% (with anticoagulants) and 25% (with aspirin); incidence of intracranial haemorrhage of 0.3%, 1.3%, or 2.0% per year; direct and indirect costs of a stroke of Kr180,000 and Kr90,000; estimated annual cost of treatment is Kr5030 for anticoagulants and Kr100 for aspirin.
  
  
  METHODS
  Total Swedish population.
  
  
  METHODS
  Direct and indirect costs of stroke saved, number of strokes prevented, and cost of preventive treatment.
  
  
  RESULTS
  Depending on the rate of haemorrhagic complications 34 to 83 patients would need to be treated annually with anticoagulants to prevent one stroke; 83 patients would need to be treated with aspirin. Giving anticoagulant treatment only would reduce costs by Kr60 million if the incidence of intracranial haemorrhage were 0.3% but would imply a net expense if the complication rate exceeded 1.3%. The total savings from giving anticoagulant (22,000 patients) and aspirin (55,000 patients) treatment would be Kr175 million per year corresponding to 2 million pounds per million inhabitants each year.
  
  
  CONCLUSIONS
  Treatment with anticoagulants and, if contraindications exist, with aspirin is cost effective provided that the risk of serious haemorrhage complications due to anticoagulants is kept low.
authors: Department of Medicine, Mariestad Hospital, Sweden.
authors: C
authors: C
authors: Gustafsson
authors: K
authors: K
authors: Asplund
authors: M
authors: M
authors: Britton
authors: B
authors: B
authors: Norrving
authors: B
authors: B
authors: Olsson
authors: L A
authors: LA
authors: Marké
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000191:economics; D002561:Cerebrovascular Disorders / Q000191:economics* / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D008875:Middle Aged; D011322:Primary Prevention / Q000191:economics*; D012307:Risk Factors; D013548:Sweden; D026712:Value of Life
chemical_list: D000925:Anticoagulants; D001241:Aspirin